Evolus, Inc.
NASDAQ: EOLS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- David Moatazedi
- Employees
- 372
- Headquarters
- Newport Beach, United States
- IPO year
- 2018
- Market cap
- $459.0M
- Website
- https://www.evolus.com
Loading EOLS…
Loading profile data…Frequently asked questions about EOLS
What does Evolus, Inc. (EOLS) do?
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the...
Where does EOLS trade?
Evolus, Inc. (EOLS) trades on the NASDAQ Global Market.
What sector is EOLS in?
Evolus, Inc. (EOLS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Evolus, Inc.?
David Moatazedi is the chief executive officer of Evolus, Inc. (EOLS).
Where is Evolus, Inc. headquartered?
Evolus, Inc. is headquartered in United States.
Does EOLS pay a dividend?
Evolus, Inc. (EOLS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EOLS go public?
Evolus, Inc. (EOLS) completed its initial public offering in 2018.